Spruce Biosciences, Inc. (NASDAQ:SPRB – Get Free Report) has earned an average rating of “Hold” from the six analysts that are currently covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a hold recommendation. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $2.50.
SPRB has been the topic of several analyst reports. Oppenheimer reissued a “market perform” rating on shares of Spruce Biosciences in a research report on Wednesday, December 11th. Guggenheim reiterated a “neutral” rating on shares of Spruce Biosciences in a research report on Thursday, December 12th. JMP Securities restated a “market perform” rating and issued a $3.00 target price on shares of Spruce Biosciences in a report on Wednesday, December 11th. HC Wainwright reiterated a “neutral” rating on shares of Spruce Biosciences in a report on Monday, December 16th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $1.50 price objective (down from $2.00) on shares of Spruce Biosciences in a research report on Wednesday, December 11th.
Read Our Latest Analysis on SPRB
Institutional Inflows and Outflows
Spruce Biosciences Trading Down 1.4 %
Shares of NASDAQ SPRB opened at $0.33 on Tuesday. Spruce Biosciences has a 1-year low of $0.32 and a 1-year high of $0.87. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.36 and a quick ratio of 5.36. The business’s 50 day moving average is $0.38 and its two-hundred day moving average is $0.44. The stock has a market capitalization of $13.65 million, a P/E ratio of -0.35 and a beta of 2.34.
About Spruce Biosciences
Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.
Featured Stories
- Five stocks we like better than Spruce Biosciences
- Why Invest in 5G? How to Invest in 5G Stocks
- Can TikTok Stock Picks Really Make You Rich?
- Conference Calls and Individual Investors
- The “Quality” Rotation: Back to Basics Investing
- NYSE Stocks Give Investors a Variety of Quality Options
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.